Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma, Large B-Cell, Diffuse

Lymphoma

Lymphoma, Follicular

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Lymphosarcoma

Follicular Lymphoma

Dose Level 1 Retifanlimab 375mg INCAGN02385 250mg INCAGN02390 200mg

Dose Level 2 Retifanlimab 500mg INCAGN02385 250mg INCAGN02390 200mg

Dose Level 3 Retifanlimab 750mg INCAGN02385 250mg INCAGN02390 200mg

Treatment:

Retifanlimab -infused over 60 minutes for C1D1 followed by a 60-minute observation period. If no infusion related reactions are observed infusion may be reduced to 30 minutes and no further observation period is needed for future cycles. If there is a reaction continue with 60 minute infusion and observation period for following cycle. Retifanlimab should always be administered first.

INCAGN02385 and INCAGN02390 -individually administered over 30 minutes one after another. For first infusions of retifanlimab, INCAGN02385 and INCAGN02390, a 4 hour observation period is necessary after completion of all infusion. If no infusion related reactions are observed, for subsequent infusions no further observation period is needed for future cycles.

Retifanlimab, INCAGN02385, INCAGN02390

Mayur Narkhede, MD

Margaret Thomas, MPH

Margaret Thomas

Amitkumar Mehta, MD

Lauren Shea, MD

Gaurav Goyal, MD

Mayur Narkhede

This study is investigating the optimal dose and the advantage in combining investigational immunotherapy drugs known as Retifanlimab, INCAGN02385 and INCAGN02390 to improve the responses to CAR T-cell therapy. Additionally, the study will investigate that triple checkpoint blockade of PD-1, TIM-3 and LAG-3 molecules will overcome CAR T-cell therapy resistance in patients with suboptimal responses.

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study)

To find the dose at which efficacy and toxicity are balanced to obtain a desirable dose.

University of Alabama at Birmingham

Assistant Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL	NCT06290622	Diffuse Large B... Lymphoma, B-Cel... Lymphoma, Folli...	Retifanlimab, I...	18 Years -	University of Alabama at Birmingham
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL	NCT06290622	Diffuse Large B... Lymphoma, B-Cel... Lymphoma, Folli...	Retifanlimab, I...	18 Years -	University of Alabama at Birmingham

Spots Global Cancer Trial Database for retifanlimab, incagn02385, incagn02390